Fig. 6

SB-334867 pretreatment had no significant effect on IPSCs in LC neurons of morphine-treated rats. a Sample traces of eIPSCs at a holding potential of − 70 mV in the presence of SB and SB plus naloxone. b SB-334867 pretreatment (3 µM) had no significant effect on eIPSCs in the absence of naloxone (repeated measure ANOVA followed by Student–Newman–Keuls test, *P < 05, n = 8) and no effect on the reduction in eIPSCs amplitude by naloxone. c Sample traces of sIPSCs during baseline and in the presence of SB and SB plus naloxone. d Left, SB-334867 pretreatment reduced sIPSCs frequency in the presence of naloxone compared to the absence of naloxone (baseline) (repeated measure ANOVA followed by Student–Newman–Keuls test, *P < 0.05, n = 8). Right, cumulative probability plots of the sIPSC inter-event interval during baseline and bath application of SB and SB plus naloxone. e Left, SB-334867 pretreatment had no significant effect on sIPSCs amplitude in either the absence or presence of naloxone compared to baseline. Right, cumulative probability plots of sIPSCs amplitude during baseline and bath application of SB and SB plus naloxone